NCT04930302: PHAROS

Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission, at Discharge and at Post-discharge Check-up: Quasi-experimental Clinical Uncontrolled Trial (PHAROS)

Completed Last updated 11 October 2023

What this trial tests

trial in Medication Errors and Other Product Use Errors and Issues in 105 participants. Completed in 1 October 2023.

Timeline

1 September 2021

Primary endpoint
30 September 2022

1 October 2023

Quick facts

Lead sponsor	National Institute of Cardiovascular Diseases, Slovakia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	105
Start date	1 September 2021
Primary completion	30 September 2022
Estimated completion	1 October 2023
Sites	1 location across Slovakia

Conditions studied

• Medication Errors and Other Product Use Errors and Issues — all drugs for Medication Errors and Other Product Use Errors and Issues →

Sponsor

National Institute of Cardiovascular Diseases, Slovakia

Who can join

18 and older, any sex, with Medication Errors and Other Product Use Errors and Issues. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to assess the impact of pharmaceutical care in collaboration with physicians on prevalence of DRPs at hospital admission and discharge in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.

The key focus area of this project will be the identification of DRPs, their occurrence and type. As a part of further research, the investigators want to analyze the a) acceptance rate of pharmaceutical intervention by physicians. Proportion of accepted interventions by physicians was calculated and b) patients' understanding of his/her pharmacotherapy assessed on a three-point scale at hospital admission.

Hypothesis:

Null hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge does not reduce prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.

Alternative hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge reduces prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.

Primary outcomes:

Change in the prevalence rate of DRPs at hospital admission vs. hospital discharge.

Secondary outcomes:

1. acceptance rate of pharmaceutical intervention by physician
2. patients' understanding of his/her pharmacotherapy

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Pharmacist-led interventions for vascular surgery patients: a prospective study on reducing drug-related problems.
   Porubcova S, Szmicsekova K, Lajtmanova K, Slezakova V, et al · · 2024 · cited 4× · PMID 39695586 · DOI 10.1186/s12913-024-12015-7
2. Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission and Discharge (PHAROS): Protocol for a Quasi-Experimental Clinical Uncontrolled Trial.
   Porubcova S, Lajtmanova K, Szmicsekova K, Slezakova V, et al · · 2025 · PMID 40106812 · DOI 10.2196/60728